Korsana Biosciences, Inc. Common Stock
KRSA
46 hedge funds and large institutions have $25.6M invested in Korsana Biosciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 8 closing their positions.
19,900% more call options, than puts
Call options by funds: $400K | Put options by funds: $2K
1.53% less ownership
Funds ownership: 54.63% → 53.11% (-1.5%)
10% less funds holding
Funds holding: 51 → 46 (-5)
37% less capital invested
Capital invested by funds: $40.7M → $25.6M (-$15.1M)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$19.8K |
| 2 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
+$16.3K |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$14.2K |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$4.36K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$112K |
| 2 |
Two Sigma Advisers
New York
|
-$52.7K |
| 3 |
Walleye Capital
New York
|
-$44K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$27K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$24K |
KRSA Hedge Fund Activity: Q1 2022 in Review
46 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q1 2022, worth a combined $25.6M — down 37% from $40.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of KRSA and 3 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 10 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $19.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $112K sold.
- 46 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $25.6M of Korsana Biosciences, Inc. Common Stock stock for Q1 2022, down 37% quarter-over-quarter.
- 3 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q1 2022 and 8 closed out, a net change of -5 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q1 2022 was Bridgeway Capital Management, an estimated $19.8K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q1 2022 was Citadel Advisors, an estimated $112K sold.
Based on aggregated 13F filings for Q1 2022.